A Conversation with Helena Cowley, CEO of Oxidien Pharmaceuticals

3 Dec

By Rory McCann, Marketing Manager & Conference Producer, LSN

Helena Cowley, MS, MBA is CEO of Oxidien Pharmaceuticals, a therapeutics company mitigating kidney stone disease by using enzyme compounds to treat secondary hyperoxaluria. We recorded our chat about the early days of Oxidien and how they’ve navigated the fundraising landscape. We discuss conferences, networking, and tools to give early-stage companies an edge when meeting with strategic partners.

To learn more about RESI and Life Science Nation’s premier partnering events this September, visit www.resipartneringweek.com. Digital RESI Partnering Week September super early bird rates apply until July 23, so sign up today to start meeting with investors and strategic partners to jumpstart your 2021 fundraising goals!


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: